Activating mutations in human acute megakaryoblastic leukemia

S Malinge, C Ragu, V Della-Valle… - Blood, The Journal …, 2008 - ashpublications.org
S Malinge, C Ragu, V Della-Valle, D Pisani, SN Constantinescu, C Perez, JL Villeval
Blood, The Journal of the American Society of Hematology, 2008ashpublications.org
Oncogenic activation of tyrosine kinase signaling pathway is recurrent in human leukemia.
To gain insight into the oncogenic process leading to acute megakaryoblastic leukemia
(AMKL), we performed sequence analyses of a subset of oncogenes known to be activated
in human myeloid and myeloproliferative disorders. In a series of human AMKL samples
from both Down syndrome and non–Down syndrome patients, mutations were identified
within KIT, FLT3, JAK2, JAK3, and MPL genes, with a higher frequency in DS than in non-DS …
Abstract
Oncogenic activation of tyrosine kinase signaling pathway is recurrent in human leukemia. To gain insight into the oncogenic process leading to acute megakaryoblastic leukemia (AMKL), we performed sequence analyses of a subset of oncogenes known to be activated in human myeloid and myeloproliferative disorders. In a series of human AMKL samples from both Down syndrome and non–Down syndrome patients, mutations were identified within KIT, FLT3, JAK2, JAK3, and MPL genes, with a higher frequency in DS than in non-DS patients. The novel mutations were analyzed using BaF3 cells, showing that JAK3 mutations were activating mutations. Finally, we report a novel constitutively active MPL mutant, MPLT487A, observed in a non–Down syndrome childhood AMKL that induces a myeloproliferative disease in mouse bone marrow transplantation assay.
ashpublications.org